Literature DB >> 20952003

Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.

Taha A Abdel-Meguid1.   

Abstract

PURPOSE: The short-term outcomes of initial detrusor injections vs combined detrusor-trigone botulinum toxin-A injections were determined in patients with spinal cord injury-neurogenic detrusor overactivity.
MATERIALS AND METHODS: Adults with refractory spinal cord injury-neurogenic detrusor overactivity who strictly discontinued anticholinergics were recruited for the study. At a 1:1 ratio patients randomly received 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm) or 200 U intradetrusor plus 100 U intratrigonal injections (combined arm). Study end points were determination of the impact on incontinence episodes, complete dryness, quality of life, reusing anticholinergics, maximum detrusor pressure, reflex volume, maximum cystometric capacity, vesicoureteral reflux and adverse events. Patients were evaluated at baseline, and 2, 8, 12 and 18 weeks after injection. Statistical significance was considered at p<0.05.
RESULTS: Analysis included 18 patients per arm with no significant baseline differences. On within group analysis all parameters improved significantly compared to baseline. On between group analysis in the detrusor vs the combined arm at week 8 incontinence decreased by 52.4% vs 80.9% (number needed to treat 1.91 vs 1.23 patients, p<0.001), complete dryness was achieved in 33.3% vs 66.7% of patients (number needed to treat 3 vs 1.5, p<0.001) and quality of life score was decreased by 46.76% vs 48.13% (number needed to treat 2.14 vs 2.08, p<0.44). The absolute difference was 60% vs 82.5% for reflex volume (p<0.001), 66.2% vs 68.4% for maximum cystometric capacity (p<0.22) and -42.3% vs -41.9% for maximum detrusor pressure (p<0.21). At week 18 anticholinergics were needed again in 9 (50%) and 4 patients (22.2%) patients, respectively. No patient showed new or upgraded vesicoureteral reflux or reported significant adverse events.
CONCLUSIONS: In the short term all parameters improved significantly in each arm. The superiority of including rather than excluding the trigone was significant.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952003     DOI: 10.1016/j.juro.2010.08.028

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  Incontinence: should we inject the trigone during botulinum toxin injection?

Authors:  Arun Sahai; Prokar Dasgupta
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

2.  Incontinence: Trigonal injection of botulinum toxin-A improves outcome.

Authors:  Sarah Payton
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

Review 3.  Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.

Authors:  Aaron Kaviani; Rose Khavari
Journal:  Urol Clin North Am       Date:  2017-08       Impact factor: 2.241

Review 4.  Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.

Authors:  Irina Soljanik
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 5.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

6.  Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.

Authors:  Gael J Yonnet; Anette S Fjeldstad; Noel G Carlson; John W Rose
Journal:  Int J MS Care       Date:  2013

Review 7.  Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events.

Authors:  N F Davis; J P Burke; E J Redmond; S Elamin; C M Brady; H D Flood
Journal:  Int Urogynecol J       Date:  2014-09-13       Impact factor: 2.894

Review 8.  How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Authors:  Maximilien Baron; Philippe Grise; Jean-Nicolas Cornu
Journal:  World J Nephrol       Date:  2016-03-06

Review 9.  The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.

Authors:  Jung Ki Jo; Kyu Nam Kim; Dong Won Kim; Yong Tae Kim; Ji Yoon Kim; Ji Yeon Kim
Journal:  World J Urol       Date:  2017-11-09       Impact factor: 4.226

10.  Botulinum toxin in neurogenic detrusor overactivity.

Authors:  Carlos Arturo Levi D'Ancona; Rúiter Silva Ferreira; Mauricio Carneiro Rassi
Journal:  Int Neurourol J       Date:  2012-09-30       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.